Technology Centre of New Jersey Tenants

Tech I Tenants

Merial Limited
75,000 square feet

Merial Limited, a Boehringer Ingelheim company, is dedicated to the discovery, development, manufacture and delivery of innovative pharmaceuticals and vaccines for all animal species. It occupies a self-standing 60,000-square-foot building as its North American pharmaceutical R&D headquarters.

Tech II Tenants

Allergan Plc
32,000 square feet

Allergan plc (NYSE:AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company. Allegan United States: March 17, 2015, Actavis (NYSE:ACT) completed the acquisition of Allergan, creating a $23 billion diversified global pharmaceutical company and a leader in a new industry model - Growth Pharma. The combined company has broad commercial reach extending across approximately 100 countries and is anchored by strong and sustainable brand franchises, a leading global generics business, a premier pipeline, highly efficient operations and an experienced management team.

Ascendia Pharmaceuticals LLC


Ascendia is a speciality pharmaceutical company dedicated to developing enhanced formulations of existing drug products, and enabling formulations for pre-clinical and clinical stage drug candidates.  Ascendia specializes in creating formulations for poorly-water soluble molecules using nano-particle technologies.  Ascendia assesses the feasibility of a broad array of formulation options in order to improve a drug’s bioavailability. Ascendia’s technologies include nano-emulsions, amorphous solid dispersions, and production of nano-crystals.  Ascendia provides development and testing services - from discovery-stage molecules to life-cycle-management projects - creating formulation solutions with enhanced biopharmaceutical properties suitable for clinical scale-up. 

Tech III Tenants

Hurel Corporation 
5,000 square feet

Hurel Corporation provides patented micro fluidic devices and cell culture that elevate the metabolic competency and endurance of cells cultured in vitro, and that simulate pharmacokinetic interactions among multiple tissues and organs. These proprietary capabilities produce unrivaled levels of physiologically relevant predictive sensitivity- “human relevance”- that define the current state of the art of hepatic and multi-tissue cell-based assays.

7,000 square feet

Orthobond uses proprietary non-polymer technology developed at Princeton University to enhance the surface characteristics of medical grade substrates. This unique attachment chemistry can be customized to provide medical companies with surfaces that improve the performance of their metallic and polymeric implants, instruments and ancillary components. Orthobond is currently focused on using this technology to create antimicrobial surfaces that may help to reduce the risk of infection associated with medical implants. Other applications include, but are not limited to, improving adhesion between surfaces, making surfaces hydrophobic or hydrophilic, or attaching specific molecules such as proteins, peptides and/or small molecules to a surface.

Rutgers Technology Center II
26,000 square feet

Rutgers Technology Center II is a 26,000-square-foot facility that will house advanced development laboratories where university researchers will collaborate with technical experts in startup ventures, established corporations and government agencies. Together they will define new capabilities for wireless computer and cell phone networks, invent lightweight yet powerful energy sources for products ranging from body implants to hybrid cars, and formulate targeted drug therapies to relieve chronic diseases. Tenants of the Rutgers Technology Center II include:


WINLAB (Wireless Information Network Laboratory) is an industry-university cooperative research center focused on wireless technology. WINLAB was founded at Rutgers University in 1989. Its research mission is to advance the development of wireless networking technology by combining the resources of government, industry and academia. The center's educational mission is to train the next generation of wireless technologies via graduate research programs that are especially relevant to industry.

Energy Storage Research Group

Energy Storage Research Group (ESRG) is a technically diverse applied research group of faculty, research staff, graduate, and undergraduate students whose charter is the research, development and advancement of the new energy storage device chemistries enabled by advancements in materials science. The group focuses on a wide range of nonaqueous and solid state chemistries, the majority of which incorporating ESRG developed nanocomposites which enable significant new abilities to deliver and store large amounts of power and energy per weight of device. The group focuses not only on the development of new materials but especially on the in-depth understanding of bulk and interfacial operational and failure mechanisms which occur on the nanoscale during the operation of these ionically active materials. The ESRG maintains over 3000 square feet of off campus laboratories dedicated to this mission. Capabilities range from fabrication and broad characterization of macro and nanoelectrode materials to the development of rechargeable energy storage devices of flat laminar design incorporating these materials to evaluate electrochemical performance.


Commercialization Center for Innovative Technologies

CCIT is one of the more significant incubation facilities in the nation dedicated to life sciences and biotechnology companies - a 46,000 sq. ft. biotech incubator in a 50-acre research park in North Brunswick in the heart of New Jersey's "Research Corridor." 

Click here for a list of tenants at the Commercialization Center for Innovative Technologies.

Tech IV Tenants

Biotechnology Development Center (BDC)

BDC is offers 32,646 sq.ft. of affordable lab and office space that is “plug-and-play” ready. The BDC is strategically designed with shared common areas and abundant amenities to create a first-class life sciences environment where post incubation tenants can focus on core scientific activities rather than administrative and facility functions.

Bionex Pharmaceuticals

Bionex’s mission is to realize bio-pharmaceutical and life sciences into commercial products and services that benefit human health. Strategically, Bionex engages in two areas of business activities. First, Bionex offers contract R&D services, from early-stage concept development to full-scale commercialization, in bio-pharmaceutical, food and cosmetic products. Second, Bionex develops and out-licenses its own proprietary formulations, technologies, and products related to drug, health food, and skin-care applications.

Chromocell Corporation
26,000 square feet

Chromocell is a life sciences company commercializing a novel technology that allows the rapid and automated production of stable cell lines expressing or suppressing multiple genes, which in turn enables the production of powerful cell-based assays and products for use in drug screening and development.